Epitalon

Epitalon (also spelled Epithalon, AEDG, or epithalon) is a synthetic tetrapeptide with the sequence Ala-Glu-Asp-Gly. It was developed in the 1980s by Russian gerontologist Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology. The peptide is a simplified four-amino-acid analog of a larger pineal-gland polypeptide called epithalamin. Khavinson's group has published the majority of the Epitalon literature spanning telomerase activation, melatonin restoration, and lifespan extension in animal models.

The molecular weight is 390 Da. The full chemical formula is C₁₄H₂₂N₄O₉. The peptide is among the smallest molecules in the "Khavinson bioregulator" class, which includes a dozen or more short peptides derived from animal organ extracts (Cytomaxes and Cytogens). Epitalon is the most studied of these, with claims that range from telomerase activation in somatic cells to circadian rhythm restoration to direct anti-tumor activity in rodent models.

The compound is not commercially produced as a pharmaceutical drug anywhere in the world. There is no Zadaxin-style approval in any major market. Production is by research-chemical synthesis labs, which is the same supply pattern as for most preclinical-dominant peptides on the FDA Category 2 list.

The Animal and Cell Evidence Base

The animal evidence base for Epitalon is substantial in volume and limited in independent replication.

Anisimov, Khavinson et al. (2003) in female CBA mice reported a 13.3 percent lifespan extension with chronic Epitalon administration compared with untreated controls, with reduced incidence of spontaneous tumors. The study is one of the most-cited lifespan claims in the longevity peptide literature.

Anisimov, Khavinson et al. (2002) in transgenic HER-2/neu mice (a model of spontaneous mammary carcinogenesis) reported reduced tumor incidence and extended lifespan with Epitalon administration. The study supports a putative chemopreventive effect tied to immune-system modulation.

Khavinson, Anisimov et al. (2000) in fruit flies reported lifespan extension after administration of the pineal peptide preparation, contributing to broader cross-species lifespan claims.

Khavinson et al. (2003) in cell culture reported telomerase activation in human fetal lung fibroblasts and extension of replicative lifespan beyond the Hayflick limit by more than 10 additional doublings.

Sanchez et al. (2025) in npj Aging confirmed telomere extension in human breast cancer cell lines (21NT, BT474) and normal epithelial and fibroblast cells, with separate mechanisms in each.

The structural problem with this evidence base is that the original Khavinson group has produced the majority of the foundational publications. Independent replication has been limited and recent (the 2025 study is the most prominent example). For a molecule whose claims are as broad as Epitalon's, the absence of large independent groups producing concordant data through the 2000s and 2010s is a substantive limitation.

The Human Evidence (Limited and Largely Open-Label)

Direct human clinical data on Epitalon is restricted to small open-label studies and case series, almost exclusively from Russian or Russian-collaborating groups.

A small human clinical trial in retinitis pigmentosa patients reported positive clinical effects in 90 percent of treated subjects. The study design was open-label without placebo control. A pulmonary tuberculosis trial reported similar uncontrolled positive findings. A 2003 Khavinson human study in elderly patients aged 60 to 80 reported increased telomere length in blood cells over a treatment period, though the sample size and methodology have been questioned.

No randomized, placebo-controlled human trial of Epitalon has been published in any peer-reviewed Western journal. This is the central limitation. Every claim about what Epitalon does in humans rests on either extrapolation from rat and cell-culture data or on open-label observational studies from a single research group.

For comparison, BPC-157 has three published human studies and a substantial controversy about publication bias from a single laboratory. Epitalon's published human evidence is smaller and has been criticized on similar grounds. The peptide is preclinical-dominant in any honest assessment of the evidence.

The proposed mechanism for Epitalon has two main components: telomerase activation and pineal-melatonin restoration.

The telomerase claim rests on the original Khavinson et al. 2003 paper and later work in cell culture. The peptide is reported to bind preferentially to methylated cytosine in DNA and to interact with the linker histone protein H1. Through these interactions, Epitalon is proposed to influence epigenetic regulation of gene expression, including reactivation of the hTERT gene (the catalytic subunit of telomerase). In normal somatic cells, hTERT is silenced after embryonic development. Reactivating hTERT in somatic cells would, in principle, allow ongoing telomere maintenance and extended replicative capacity.

A 2025 confirmatory study by Sanchez and colleagues at Texas Tech University extended the original findings, reporting that Epitalon increases telomere length in multiple human cell lines through telomerase upregulation in normal cells and through alternative lengthening of telomeres (ALT) in cancer cell lines. The dual-mechanism finding raises mechanistic questions about specificity but does provide some independent replication of the original Khavinson observations.

The melatonin claim is supported by animal studies showing that Epitalon administration restores the nocturnal melatonin rhythm in older rats whose pineal function had declined. The mechanism appears to involve direct stimulation of pineal pinealocytes. The clinical relevance in humans is largely inferred from animal data, as direct human pineal-function trials with Epitalon are absent from the published peer-reviewed literature.

The third proposed mechanism is gene expression modulation. Khavinson's group has reported broad effects on gene expression patterns in multiple tissues, with claims that the peptide normalizes age-altered transcription. The mechanism is loosely characterized and not specifically distinguished from non-specific effects.

Epitalon is preclinical-dominant. No randomized, placebo-controlled human trial has been published in any peer-reviewed Western journal. The effects below are reported in cell culture, rodent models, and small open-label observational studies, almost exclusively from the Khavinson research group in St. Petersburg.

Cell Culture Telomerase and Telomere Outcomes

The most-cited Epitalon finding is the in vitro telomerase activation result.

Khavinson et al., 2003 (Bulletin of Experimental Biology and Medicine). Human fetal lung fibroblasts in culture, exposed to Epitalon, showed telomerase activation and extended replicative lifespan beyond the Hayflick limit by more than 10 additional cell doublings. The Hayflick limit (the maximum number of times normal somatic cells can divide before senescence) is typically 40 to 60 doublings in fibroblasts. Extending this by 10+ doublings is a substantial in vitro finding if the result is real and generalizable.

Sanchez et al., 2025 (npj Aging). Independent confirmation at Texas Tech University. Epitalon increased telomere length in normal human epithelial cells and fibroblasts through telomerase upregulation. The same study also reported telomere extension in human breast cancer cell lines (21NT and BT474), but through the alternative lengthening of telomeres (ALT) pathway, not through telomerase. The dual-mechanism finding is the first significant independent replication of the original Khavinson observations, but the ALT-pathway activation in cancer cells is mechanistically concerning. ALT is associated with tumor progression in subsets of human cancers.

Animal Lifespan and Tumor Outcomes

Anisimov, Khavinson et al., 2003 (female CBA mice). Chronic Epitalon administration produced a 13.3 percent mean lifespan extension compared with untreated controls. Maximum lifespan was also extended. Spontaneous tumor incidence was reduced compared with controls. The lifespan effect is among the largest reported for any peptide intervention in a mouse model.

Anisimov, Khavinson et al., 2002 (HER-2/neu transgenic mice). In a model of spontaneous mammary carcinogenesis, Epitalon reduced tumor incidence and extended lifespan. The mechanism is proposed to involve immune-system modulation and direct anti-tumor effects.

Rat lifespan studies (Khavinson group, 2000s). Reported lifespan extensions ranging from approximately 24 percent in some rat strains. The rat studies use various inbred and outbred strains and chronic dosing protocols. Independent replication outside the Khavinson group is limited.

Drosophila (fruit fly) studies (Khavinson, Anisimov et al., 2000). Lifespan extension reported in fly populations exposed to the pineal peptide preparation. The cross-species pattern (lifespan extension in cells, mice, rats, and flies) is the basis for the broader anti-aging claim.

Pineal Melatonin Restoration (Rodent)

In aged rats with reduced nocturnal melatonin secretion, Epitalon administration restored a more youthful melatonin rhythm. The mechanism is proposed to involve direct stimulation of pineal pinealocytes. The clinical relevance in humans is inferred from this rodent data and has not been characterized in direct human pineal-function trials.

Some users report subjective improvements in sleep quality and continuity during Epitalon use. Whether the human pineal response to Epitalon is similar to the rat response has not been established in published controlled trials.

Human Open-Label Observational Studies

Retinitis pigmentosa. A small Russian open-label study reported positive clinical effects in approximately 90 percent of treated subjects. Without a placebo control or randomization, the magnitude of the true Epitalon-specific effect cannot be estimated.

Pulmonary tuberculosis. A separate open-label Russian study reported clinical improvements in treated subjects. Same methodological limitations as the retinitis pigmentosa study.

Elderly telomere length (Khavinson 2003 human study). Treatment of elderly patients aged 60 to 80 was reported to increase telomere length in blood cells. Sample size was small. Methodology has been questioned in subsequent reviews.

None of the published human studies meets the methodological standard expected of a Phase 2 or Phase 3 trial in Western pharmaceutical development.

Subjective Off-Label Effects

Adult off-label users report a pattern of subjective effects that have not been controlled in any trial.

Improved sleep quality. Most commonly reported. Plausibly related to the pineal melatonin mechanism if the rodent finding translates.

Subjective energy and well-being. Reported in open-label and observational settings.

Skin elasticity. Reported in cosmetic-medicine contexts. Observational rather than controlled.

General "anti-aging" effects. Difficult to quantify, often reported in the absence of any defined endpoint.

None of the subjective off-label effects has trial-grade evidence backing.

What Epitalon Has NOT Been Shown to Do in Humans

Several commonly attributed effects lack trial-grade human evidence.

Demonstrated lifespan extension in humans. No human lifespan trial has been completed. The animal data does not directly translate.

Documented cancer prevention. The animal data suggests reduced tumor incidence, but the same 2025 cell-culture study showed ALT-pathway activation in cancer cells, which is mechanistically concerning.

Clinically meaningful telomere extension in adult humans. The 2003 elderly study reported increased telomere length, but the methodology has been questioned and no controlled trial has confirmed the finding.

Reversal of age-related disease in any randomized controlled trial. No RCT exists.

This compound is on the World Anti-Doping Agency (WADA) Prohibited List under section S0 as a non-approved substance. Use in competitive sport is a doping violation.

The Khavinson Group Protocol

The dosing pattern used in the Khavinson research group's published animal and observational human work is the de facto standard for Epitalon. There is no FDA-approved or label-derived dose to compare against, so the Khavinson protocol functions as the reference dose.

Standard protocol: 5 to 10 mg administered subcutaneously once daily for 10 to 20 days, repeated as 2 to 3 cycles per year. The cycle structure (10-20 days on, 3-6 months off) is the typical Khavinson approach and is the basis for most adult off-label dosing patterns currently in circulation.

The dose is not weight-adjusted. The protocol comes from animal-to-human dose-scaling rules used by the Khavinson group rather than from a formal Phase 1 dose-finding trial. No published dose-response curve in humans exists for Epitalon.

Alternative Dosing Patterns

Adult off-label users in compounding and research-chemical contexts have used several alternative patterns, none of which has trial-based justification.

Continuous daily microdosing: 1 to 3 mg subcutaneously daily for extended periods (months). The rationale is to maintain a more constant exposure rather than pulsed cycles. No published pharmacokinetic data supports any particular continuous-dose protocol over the Khavinson cycle.

Higher-dose short cycles: 10 to 20 mg daily for 10 days, repeated. The rationale is unclear. There is no published evidence that higher doses produce proportionally larger biological effects.

Twice-yearly cycles only: 10-20 day cycles in spring and fall, with no other dosing in between. The rationale comes from circadian-and-seasonal-rhythm arguments about pineal function. Not evidence-based.

Pharmacokinetics

No published Phase 1 pharmacokinetic study of Epitalon in humans exists in peer-reviewed Western journals. The pharmacokinetics are largely inferred from the small-peptide class.

For a 4-amino-acid peptide of approximately 390 Da, subcutaneous absorption is expected to be relatively rapid (peak concentration within 30 to 60 minutes), and the plasma half-life is expected to be short (minutes to a few hours) due to rapid proteolytic degradation. This pharmacokinetic profile is consistent with the daily-dosing pattern used in the Khavinson protocol.

Whether the brief plasma exposure is sufficient to produce the proposed downstream telomerase and pineal effects is a mechanistic question that the published literature does not adequately address. Some proposed mechanisms (epigenetic gene expression changes) would require very different exposure patterns than what the short half-life would produce.

Administration Routes

Subcutaneous injection is the primary route used in the Khavinson protocols and in adult off-label use. Injection sites are typically the abdomen, thigh, or upper arm, with site rotation. The peptide is reconstituted from lyophilized powder with bacteriostatic water.

Intranasal administration has been used in some Russian research formulations. Bioavailability and dose equivalence to subcutaneous have not been characterized in peer-reviewed Western publications. Some adult off-label users prefer this route for convenience.

Oral administration is not well-characterized for Epitalon. The tetrapeptide is small enough to potentially survive partial digestion, but absorption efficiency is unclear. The Khavinson group has produced some oral formulation work without published bioequivalence data versus the subcutaneous route.

Reconstitution (10 mg Vial)

Epitalon is supplied as lyophilized powder, typically in vials of 10 mg or 50 mg. Reconstitution uses bacteriostatic water at a working concentration of 1 to 5 mg/mL.

For a 10 mg vial: Adding 2 mL of bacteriostatic water yields 5 mg/mL solution. A 5 mg dose delivers in 1 mL of solution. A 10 mg dose delivers in 2 mL.

For a 10 mg vial at 2.5 mg/mL: Adding 4 mL of bacteriostatic water. A 5 mg dose delivers in 2 mL. A 10 mg dose delivers in 4 mL.

Once reconstituted, the peptide is stable for 2 to 4 weeks refrigerated based on general short-peptide stability rules. Specific Epitalon stability data in peer-reviewed Western publications is limited.

Cycling Rationale

The 10-20 day cycle followed by months off is the most distinctive feature of the Khavinson protocol compared with daily dosing of other peptides. The proposed rationale is that the biological effects (epigenetic gene expression changes, telomerase reactivation) persist beyond the dosing period, so continuous administration is unnecessary. The published evidence for sustained post-dosing effects is from animal studies in the Khavinson group and has not been confirmed in independent human work.

Why Adult Epitalon Dosing Has Not Been Validated

The Khavinson protocol has been used in adult off-label settings for two decades without a published Phase 1 dose-finding trial, a Phase 2 efficacy trial, or any randomized controlled human study. The dose, route, and cycle pattern come from a single research group's animal-to-human extrapolation rather than from clinical-trial methodology. Whether the 5 to 10 mg daily dose is optimal, suboptimal, or unnecessarily high in adult humans is not established. The peptscope editorial position is to report the Khavinson protocol as the de facto standard while flagging the absence of trial-based validation.

The published safety record for Epitalon is largely descriptive and uncontrolled. Animal toxicology studies have not reported dose-limiting toxicity at the doses tested. The open-label human studies have not reported serious adverse events.

What the safety database does not include is what concerns regulators most. There are no long-term randomized safety studies. There is no Phase 1 pharmacokinetic data published in peer-reviewed Western journals. The long-term consequences of telomerase activation in adult somatic cells, if the mechanism is real, are theoretically concerning for cancer risk. Telomerase reactivation is one of the hallmarks of tumor cells, and selective telomerase activation in normal somatic cells without affecting malignant clones is a difficult pharmacologic goal that the published Epitalon literature does not adequately address.

The 2025 Sanchez paper that confirmed telomere extension also reported that the peptide activates the ALT (alternative lengthening of telomeres) pathway specifically in cancer cells. ALT is associated with tumor progression in subsets of human cancers. Whether this represents a safety concern or an experimental artifact of the cell-culture model is unclear, but it warrants serious investigation before broad human use is supported.

The FDA Category 2 designation reflects this risk-benefit imbalance: small published safety database, broad mechanistic claims, theoretical cancer concerns at the mechanistic level. The agency is saying the evidence is insufficient to support compounding, not that documented harm has occurred.

Epitalon sits in a different evidence position from other commonly discussed longevity peptides.

MOTS-c is a mitochondrial-derived peptide with early human pharmacokinetic data and active Phase 1/2 development by CohBar. Its mechanism (AMPK pathway activation, metabolic regulation) is mechanistically distinct from Epitalon's telomere focus and has more independent research support.

SS-31 (elamipretide) received FDA approval in September 2025 for Barth syndrome, making it the only mitochondrial peptide with current approval. The clinical-trial evidence base is orders of magnitude larger than Epitalon's. Mechanism (cardiolipin binding, mitochondrial membrane stabilization) is unrelated to telomere biology.

Humanin has preclinical data on neuroprotection and metabolic regulation but limited human trial data, similar to Epitalon's evidence position.

Among the "Khavinson bioregulators" specifically, Epitalon has the largest published evidence base. The remaining Cytomaxes and Cytogens (Vilon, Livagen, Cortexin, Pinealon, and others) have even smaller published datasets and rely almost entirely on the same Russian research group.

For a longevity intervention with stronger published support, rapamycin, metformin, and SS-31 (now approved) sit in a different evidence category. Epitalon belongs to the speculative tier where mechanistic claims have outrun the human data needed to support them.

For informational and educational purposes only. Not medical advice. Not for human consumption unless prescribed by a licensed physician for an FDA-approved indication. Consult a qualified healthcare provider before using any peptide or pharmaceutical product.